CK-869 NEW
| Price | $33 | $53 | $107 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-21 |
Product Details
| Product Name: CK-869 | CAS No.: 388592-44-7 |
| Purity: 99.85% | Supply Ability: 10g |
| Release date: 2026/04/21 |
Product Introduction
Bioactivity
| Name | CK-869 |
| Description | CK-869, an Actin-Related Protein 2/3 (ARP2/3) complex inhibitor with an IC50 of 7 μM, is a valuable tool for investigating the Arp2/3 complex. |
| Cell Research | Cells were treated in suspension with different concentrations of the compounds, allowed to adhere to the surface of a tissue culture dish for one hour, washed and the number of adherent cells counted and presented as a fraction of untreated cells (10X lens, 10 fields/condition).?For cell spreading assays, cells were treated with CK-869 in suspension, plated on coverslips coated with 5 μg/ml fibronectin for imaging[1]. |
| In vitro | CK-869 inhibits comet tail formation by L. monocytogenes with an IC50 value of 7 μM.It also impairs cell adhesion and cell spreading in MCF10A human breast epithelial cells[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 75 mg/mL (190.22 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.07 mM), Sonication is recommended. |
| Keywords | MicrotubuleAssociated | Microtubule Associated | Inhibitor | inhibit | CK-869 | CK869 | CK 869 | Arp2/3 Complex | Actin-related protein 2/3 complex |
| Inhibitors Related | Flubendazole | N-Phenylbenzylamine | Mebendazole | 4-Isopropoxybenzoic acid | Pregnenolone acetate | Oxfendazole | α-Cyclodextrin | Methylene Blue trihydrate | Paclitaxel | 4'-Demethylepipodophyllotoxin | Albendazole | Colchicine |
| Related Compound Libraries | Bioactive Compound Library | Microtubule-Targeted Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | High-Efficiency Gene Editing Small Molecule Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
|
VIP5Y
|
Changsha Staherb Natural Ingredients Co., Ltd.
|
2026-07-03 | ||
|
Shaanxi Cuikang Pharmaceutical Technology Co., Ltd
|
2026-03-04 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY